de en
  • Paion GmbH
  • Company

    About PAION

    1. History
    2. Management
    3. Supervisory Board

    Information

    1. Events
    2. Information Request
  • Products

    Remimazolam

    1. About Remimazolam
    2. UK SMPC for remimazolam
    3. UK PIL for remimazolam

    Angiotensin II

    1. About Angiotensin II

    Eravacycline

    1. About eravacycline
  • Career

    What does PAIONeering mean to us?

    What PAIONeers can expect

    1. Professional Development

    Job offers

  • Media and Investors

    At a glance

    1. General Information
    2. Contact

    Newsroom

    1. Press Releases
    2. Ad-hoc Releases
    3. Directors' Dealings
    4. Holdings in company

    Information on shares

    1. Chart & Fact sheet
    2. Analysts
    3. Capital actions
    4. Information on CeNeS Acquisition

    Investorcenter

    1. Financial Reports
    2. Presentations
    3. Corporate calendar
    4. Information Request

    Corporate Governance

    1. Declaration on Corporate Governance
    2. Articles of Association
    3. Declaration of Conformity
    4. Code of Conduct
    5. By-Laws Supervisory Board
    6. Compensation Management Board and Supervisory Board

    Annual general meeting

    2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
  • Contact

    Germany

    UK

    Nordic Countries

    Netherlands

prev next
  • Media and Investors  » 
  • Newsroom  » 
  • Press Releases  » 
  • 2015
  • 12/01/2015

    PAION announces initiation of U.S. clinical safety trial of Remimazolam in high risk patients undergoing colonoscopy

    • PDF

  • 11/11/2015

    PAION AG reports results for the first nine months 2015

    • PDF

  • 10/27/2015

    Launch of new PAION Corporate Website

    • pdf

  • 10/14/2015

    PAION receives positive feedback from Japanese authority PMDA about production of Remimazolam for Japan

    • PDF

  • 10/12/2015

    Remimazolam posters at Anesthesiology® 2015

    • PDF

  • 08/27/2015

    Juergen Raths, MD appointed as Chief Operating Officer at PAION AG

    • PDF

  • 08/12/2015

    PAION AG reports financial results for the first half-year of 2015

    • PDF

  • 08/11/2015

    PAION starts EU Phase III study with Remimazolam in the indication general anesthesia

    • PDF

  • 08/07/2015

    Timothy E. Morris joins PAION, Inc. as a non-executive Director

    • PDF

  • 07/23/2015

    PAION completed Remimazolam know-how and tech transfer from Ono

    • PDF

  • 07/07/2015

    Dr. Mariola Söhngen will leave management board of PAION AG as of 31 October 2015 and PAION plans new composition of executive management

    • PDF

  • 06/08/2015

    PAION announces initiation of second U.S. Phase III clinical trial of Remimazolam for procedural sedation during bronchoscopy

    • PDF

  • 05/13/2015

    Q1 2015: Earnings call and webcast (in English) on 13 May 2015

    • MP3

    • PDF

  • 05/13/2015

    PAION AG reports financial results for the first quarter 2015

    • PDF

  • 05/07/2015

    David Bernstein, M.D. joins PAION as medical advisor

    • PDF

  • 03/31/2015

    PAION announces initiation of U.S. Phase III clinical trial of Remimazolam for procedural sedation during colonoscopy

    • PDF

  • 03/18/2015

    PAION AG reports financial results for the full year 2014

    • PDF

  • copyright © PAION AG I all rights reserved
  • Imprint
  • Privacy Statement
  • General Terms and Conditions
Paion

Heussstraße 25 | 52078 Aachen | Deutschland

Tel.: +49 241 4453-0 | Fax.: +49 241 4453-100 | e-mail: info@paion.com

Company
  1. About PAION +
    1. History
    2. Management
    3. Supervisory Board
  2. Information +
    1. Events
    2. Information Request
Products
  1. Remimazolam +
    1. About Remimazolam
    2. UK SMPC for remimazolam
    3. UK PIL for remimazolam
  2. Angiotensin II +
    1. About Angiotensin II
  3. Eravacycline +
    1. About eravacycline
Career
  1. What does PAIONeering mean to us?
  2. What PAIONeers can expect +
    1. Professional Development
  3. Job offers
Media and Investors
  1. At a glance +
    1. General Information
    2. Contact
  2. Newsroom +
    1. Press Releases
    2. Ad-hoc Releases
    3. Directors' Dealings
    4. Holdings in company
  3. Information on shares +
    1. Chart & Fact sheet
    2. Analysts
    3. Capital actions
    4. Information on CeNeS Acquisition
  4. Investorcenter +
    1. Financial Reports
    2. Presentations
    3. Corporate calendar
    4. Information Request
  5. Corporate Governance +
    1. Declaration on Corporate Governance
    2. Articles of Association
    3. Declaration of Conformity
    4. Code of Conduct
    5. By-Laws Supervisory Board
    6. Compensation Management Board and Supervisory Board
  6. Annual general meeting +
    1. 2022
    2. 2021
    3. 2020
    4. 2019
    5. 2018
    6. 2017
    7. 2016
    8. 2015
    9. 2014
    10. 2013
    11. 2012
    12. 2011
Contact
  1. Germany
  2. UK
  3. Nordic Countries
  4. Netherlands
Cookie Settings

This website uses cookies.

Some of them are essential and required for running the website. Others improve your user experience and may be activated or deactivated at your discretion.

Accept all Save
Privacy Statement Imprint